©1995 by The American Society for Biochemistry and Molecular Biology, Inc.
Cloning and Characterization of a Human Protein Kinase with Homology to Ste20 (*)

(Received for publication, May 5, 1995; and in revised form, July 10, 1995)

Caretha L. Creasy (§) Jonathan Chernoff

From the Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES

ABSTRACT

A human protein kinase (termed MST1) has been cloned and characterized. The MST1 catalytic domain is most homologous to Ste20 and other Ste20-like kinases (62-65% similar). MST1 is expressed ubiquitously, and the MST1 protein is present in all human cell lines examined. Biochemical characterization of MST1 catalytic activity demonstrates that it is a serine/threonine kinase, and that it can phosphorylate an exogenous substrate as well as itself in an in vitro kinase assay. Further characterization of the protein indicates MST1 activity increases approximately 3-4-fold upon treatment with PP2A, suggesting that MST1 is negatively regulated by phosphorylation. MST1 activity decreases approximately 2-fold upon treatment with epidermal growth factor; however, overexpression of MST1 does not affect extracellular signal-regulated kinase-1 and -2 activation. MST1 is unaffected by heat shock or high osmolarity, indicating that it is not involved in the stress-activated or high osmolarity glycerol signal transduction pathways. Thus MST1, although homologous to a member of a yeast MAPK cascade, is not involved in the regulation of a known mammalian MAPK pathway and potentially regulates a novel signaling cascade.


INTRODUCTION

Regulation of cell growth and differentiation utilizes a complex mechanism of signaling involving the catalytic activities of protein kinases and phosphatases. The mechanisms used in signal transduction are well conserved in all eukaryotes. In mammalian cells external stimuli acting on both growth factor receptors and some G protein-coupled receptors signal through a kinase cascade resulting in the activation of members of the mitogen-activated protein kinase (MAPK) (^1)family, ERK1 and ERK2(1, 2, 3) . ERK1/2 phosphorylate a variety of substrates including transcription factors and other kinases(4, 5, 6) . Activation of ERK1/2 requires phosphorylation of both tyrosine and threonine residues which is mediated by a dual specific kinase termed MEK(7, 8) . MEK activation may represent a convergence point for signaling since it is known that both Raf and MEKK phosphorylate MEK(9, 10, 11) . Studies involving pheromone signaling in both budding (Saccharomyces cerevisiae) and fission (Schizosaccharomyces pombe) yeast have revealed that similar signal transduction mechanisms operate in these evolutionarily divergent organisms(12) . Additional signal transduction cascades have since been identified in S. cerevisiae and more recently in mammalian cells. These include pathways responsible for cell wall biosynthesis, hyperosmotic sensing, and spore formation in S. cerevisiae and those activated by stress and high osmolarity in mammalian cells(13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23) . Structural homologies exist between the mammalian and yeast pathways at the level of MAPK, MEK, and MEKK(11) . Complementation studies in the pheromone response pathway with mammalian homologs indicate that the proteins are also somewhat functionally related(24, 25) .

In S. cerevisiae a serine/threonine kinase termed Ste20 acts upstream of the MEKK, Ste11, and downstream of the pheromone-linked G protein in the mating pathway(26, 27) . The recent identification of rat and human homologs to Ste20, termed p65, indicates that an additional level of conservation exists among signal transduction cascades from distantly related species (28) . (^2)However, the identification of a Ste20 homolog in S. cerevisiae, termed Sps1, which is involved in the spore formation pathway, suggests that conservation at this level in the cascade may be more complex(18) . Sps1, while similar to both Ste20 and p65 throughout the catalytic domain, does not share any significant homologies outside this domain.

We have cloned and characterized a human protein kinase with a similar degree of homology to Ste20, p65, Sps1, and a human protein kinase termed GC kinase(29) . Because of its homology to Ste20 we have termed this protein MST1 (Mammalian Sterile Twenty-like). Northern analysis indicates that MST1 is ubiquitously expressed. Biochemical characterization of MST1 indicates that it is a serine/threonine kinase and that it may be negatively regulated by phosphorylation. MST1 does not function in the MAPK signal transduction cascade nor is its activity increased in response to growth factors, heat shock or high osmolarity suggesting that it is involved in an as yet unidentified signal transduction pathway.


EXPERIMENTAL PROCEDURES

cDNA Cloning and Sequencing

Degenerate oligonucleotide primers, 5`-CGGGATCCGGNGARHTNATGGCNGTNAARCARGT-3` and 5`-CGGAATTCVTYNACNAYYTCNGGNSYCATCCARAA-3` encoding the sense and antisense strands of amino acids, GE(I/L/M)MAVKGV and FWM(A/S/T/R/G)PE(V/M/I)V(D/E/K/N), flanked by restrictions sites for BamHI and EcoRI, respectively, were used to amplify DNA from a human lymphocyte cDNA library (30) using Vent polymerase (New England Biolabs). An aliquot of the reaction was used for a second round of amplification using the same 5` oligonucleotide and 5`-CGGAATTCRTTNGCNCCYTTNAYRTCNCKRTG-3`, which encodes the antisense strand of H(R/S)D(V/M/I)KGAN. A polymerase chain reaction was carried out using an Idaho technologies thermal cycler (an initial denaturation at 94 °C for 1 min, 30 amplification cycles of 1 s at 94 °C, 5 s at 35 °C, 15 s at 65 °C, followed by 1 min at 74 °C). A fragment of approximately 340 bp was obtained and used to screen 5 times 10^5 plaques from the same cDNA library using standard methods(31) . Those clones containing the largest inserts were restricted and both strands sequenced using Sequenase 2.0 (U.S. Biochemical Corp.). Amino acid sequence comparisons were made using the University of Wisconsin Genetics Computer Groups programs, Pileup and Prettyplot (plurality = 3.5, threshold = 1.00).

Plasmids

The plasmids, pJ3M-MST1, pJ3H-MST1, or pCMV5M-MST1, were used in transient transfections where indicated. Oligonucleotide primers, 5`-CGGGATCCGCCATGGAGACGGTACAG-3` and 5`-GAATTCCTCGAGGCCACG-3` (linker sequence) were used to amplify the MST1 cDNA. The amplified fragment was digested with BamHI and EcoRI (at bp 1529, a site 3` to the stop codon at 1483 bp) and subcloned into pJ3M or pJ3H, SV40-based vectors containing a myc-epitope tag or hemagglutinin epitope tag (HA) 5` to the BamHI site(32) . To construct pCMV5-MMST1, Myc-MST1 was removed from pJ3M-MST1 as a HindIII-XhoI fragment and subcloned into the HindIII-SalI site of pCMV5(33) . The plasmid pJ3H-ERK contains ERK1 cloned as a BamHI-EcoRI fragment into pJ3H(32) .

Northern Blot Analysis

An adult human multitissue Northern blot (Clontech) was hybridized with a random primed (Stratagene) P-labeled MST1 probe generated from either a region encoding the catalytic domain (nucleotides 178-481) or the 3`-untranslated region (nucleotides 1529-1930). Hybridization was carried out at 65 °C essentially as described elsewhere(31) . The integrity of the mRNA was confirmed via hybridization to a P-labeled actin probe.

Cell Culture

Cell lines were grown in the appropriate growth media (AG876, RPMI 1640, 10% fetal bovine serum; NIH3T3, DMEM, 10% calf serum; HeLa, COS, 293, A431, and Rat1A, DMEM, 10% fetal bovine serum; PC12, DMEM, 10% horse serum, 5% fetal bovine serum) containing 50 units/ml penicillin, 50 µg/ml streptomycin, and 100 µg/ml kanamycin. When needed COS cells were transfected using lipofectamine according to the manufacturer's protocol (Life Technologies, Inc.). For lysates, cells were grown to confluence, washed twice in phosphate-buffered saline, and lysed in Nonidet P-40 lysis buffer (20 mM Tris-HCl, pH 8.0, 137 mM NaCl, 10% glycerol, 1% Nonidet P-40) supplemented with 50 mM NaF, 10 mM beta-glycerol phosphate, 1 mM sodium vanadate, 2 mM phenylmethylsulfonyl fluoride, and 1 µg/ml aprotinin. Where indicated, cells were starved in DMEM lacking serum for 20 h and treated with EGF (400 ng/ml) for either 1, 5, 10, or 30 min prior to cell lysis. Lysates were clarified via centrifugation at 12,000 times g for 5 min, and protein concentrations were determined using BCA protein reagent (Pierce). For immunoprecipitations, lysates were incubated with either 1.5 µl/mg polyclonal antiserum raised against amino acids 276-487 of MST1 (m1-45), 1.5 µl/mg anti-Myc antibody (9E10)(34) , or 3.0 µl/mg anti-HA antibody (12CA5) (Berkeley Antibodies, Inc.) for 1 h at 4 °C with rocking. Protein A-Sepharose beads (Sigma, 12 µg/µl) were added and incubation continued for an additional 45 min. The beads were washed three times in Nonidet P-40 lysis buffer and resuspended in SDS sample buffer(35) . Immunoprecipitated complexes to be treated with PP2A were divided equally into new tubes, supernatants were removed, and beads were resuspended in 20 µl of 62.5 mM Tris, pH 7.4, 0.05 mg/ml bovine serum albumin to which 0.5 unit of PP2A (a gift from Heng-Chun Li, Mount Sinai School of Medicine) in 20 mM Tris, pH 7.4, 10 mM beta-mercaptoethanol, 0.1 mM EGTA, 50% glycerol, or buffer alone was added. The reaction mixtures were incubated at 30 °C for 1 h followed by three washes in Nonidet P-40 lysis buffer. The beads were then resuspended in SDS sample buffer and boiled for 5 min.

Western Blot Analysis

Proteins resolved on a 10% SDS-polyacrylamide gel (35) were transferred to a PVDF membrane in transfer buffer (12.5 mM Tris, 96 mM glycine, 20% methanol). The membrane was blocked for at least 1 h in 5% nonfat milk, 1 times TBS-T20 (50 mM Tris, 150 mM NaCl, 0.05% Tween-20) and immunoblotted with m1-45 (1:7500), 9E10 (1:2500), 12CA5 (1:2500), or anti-MAPK (1:2500) (Z033, Zymed). Immunoblotting was performed in 3% nonfat milk, 1 times TBS-T20 for 1 h at room temperature. Following three washes in 1 times TBS-T20 for 5 min each, goat-alpha-rabbit conjugated alkaline phosphatase antibodies (1:5000) (Alpha Quest) or goat-alpha-mouse conjugated horseradish peroxidase (1:10000) (Promega) were added. Incubation continued for 45 min at room temperature followed by three washes with 1 times TBS-T20. Blots incubated with alkaline phosphatase antibodies were developed as described elsewhere (36) , while those incubated with horseradish peroxidase were developed using Renaissance Chemiluminescence Reagent (DuPont NEN).

Kinase Assays

Immunoprecipitated MST1 was incubated with 5 µg of myelin basic protein (Sigma) in 20 µl of kinase buffer (40 mM Hepes, pH 7.5, 10 mM MgCl(2)) containing 20 µM ATP and 1.0 µCi of ATP for 40 min at 30 °C. The reaction was terminated by the addition of an equal volume of 2 times SDS sample buffer and boiling for 5 min. In gel kinase assays were performed as described elsewhere (37, 38) in the absence of an exogenous substrate or in the presence of 0.25 mg/ml myelin basic protein where indicated.

Phosphoamino Acid Analysis

Radioactive bands excised from dried gels were treated essentially as described elsewhere(39) , except that the separation was carried out in only one dimension using a pH 2.5 buffer (5.9% (v/v) glacial acetic acid, 0.8% (v/v) formic acid (88%), 0.3% (v/v) pyridine, 0.3 mM EDTA) at 20 mA for 45 min(40) .


RESULTS

Cloning and Sequencing MST1

Degenerate oligonucleotide primers, corresponding to conserved amino acids present in the catalytic domains of serine/threonine kinases, were used to amplify cDNA from a human lymphocyte cDNA library(30) . One fragment appeared to encode a kinase similar to Ste20 from S. cerevisiae. This fragment was then used to probe the same cDNA library. The longest fragment was 2 kb and contained a 487-amino acid open reading frame with a strong Kozak sequence (GCCATGG) at the potential initiation codon (Fig. 1). At the 3` end there is a poly(A) tail; however, there does not appear to be a polyadenylation signal.


Figure 1: Nucleotide and predicted amino acid sequence of MST1. The proposed initiation codon is in bold. The region amplified using degenerate oligonucleotides is underlined. Amino acids (in one-letter code) and nucleotides are numbered at the left and right, respectively.



Amino Acid Sequence Analysis

The MST1 cDNA encodes a 487-amino acid protein with an expected molecular mass of 55,721 Da. The amino-terminal half of the protein contains the 11 subdomains characteristic of a serine/threonine kinase (Fig. 2)(42) . The carboxyl-terminal half of the protein lacks any notable sequence motifs; however, this portion of the protein is quite acidic (pI of 4.4). The MST1 kinase domain is most similar to Ste20, p65, Sps1, and GC kinase (64, 64, 62, and 65%, respectively). While Ste20 expressed at high levels is able to complement a ste20 null allele, MST1 expressed from the same promoter does not complement, indicating that these genes are not functionally homologous (data not shown). Unlike Ste20 and p65, MST1, Sps1, and GC kinase do not contain recognizable Cdc42/Rac1 binding elements. Overall the organization of MST1 is more similar to that of Sps1 and GC kinase which have a putative regulatory domain at the carboxyl terminus; however, there does not appear to be any striking similarities within this domain.


Figure 2: A comparison of the MST1 catalytic domain to Ste20, p65, Sps1, and GC kinase. A, the 11 subdomains conserved in protein kinases are indicated in roman numerals above the sequences. The numbers at the right indicate amino acids. B, schematic shows the percent amino acid similarity between MST1 and related kinases. The percentages were obtained by comparing the catalytic domains of each deduced amino acid sequence.



Expression of MST1

The expression of MST1 was examined in a variety of adult human tissues. A probe specific to the kinase domain (encompassing nucleotides 178-481) identified a transcript at approximately 7 kb in all tissues and another at approximately 3.4 kb which is very abundant in kidney, placenta, and skeletal muscle tissues (Fig. 3). However, a probe specific to the 3`-untranslated region (nucleotides 1529-1930) hybridized to only the larger 7-kb transcript (data not shown). The smaller transcript is most likely either a homolog to MST1 or a splice variant of the larger transcript.


Figure 3: Expression pattern of MST1. A human multitissue blot containing poly(A) RNA (Clontech) was probed with nucleotides 178-481 encoding amino acids 55-154 of MST1 (A). B, the same blot probed with actin to check the integrity of the RNA.



Western Blot Analysis

Consistent with the mRNA expression pattern, a polyclonal antiserum (m1-45) directed against the carboxyl terminus of MST1 (amino acids 276-487) identified a 56-kDa polypeptide in all human cell lines examined (AG876, A431, 293, and HeLa) and also in monkey cells (COS) (Fig. 4A). A less prominent, slightly smaller polypeptide was also identified in AG876, 293, and A431 cells. In addition, the 56-kDa polypeptide could be immunoprecipitated from COS cells using the same antibody. However, MST1 was not detected in either rat cell line (Rat 1A or PC12) and was detected at very low levels in mouse cells (NIH3T3). When used to transfect COS cells, Myc-epitope tagged MST1 (Myc-MST1) was detected as a slightly slower migrating band than endogenous MST1 (Fig. 4A). This increase in molecular mass is consistent with the size of the Myc-epitope.


Figure 4: Characterization of the MST1 protein. A, Western blot analysis. Cell lysates from either AG876, 293, HeLa, A431, Rat1A, PC12, NIH3T3, or COS cells (lanes 1-8, 15 µg/lane) MST1 immunoprecipitated from COS cells (lane 9) and immunoprecipitated Myc-epitope tagged MST1 (lanes 11) from transiently transfected COS cells (lane 10). Immunoblotting with the anti-MST1 antibody (m1-45) and subsequent detection was performed as described under ``Experimental Procedures.'' B, in vitro kinase assays. Endogenous MST1 was immunoprecipitated from COS cells with m1-45 (lane 1). As a negative control an equal amount of protein was immunoprecipitated with preimmune serum (lane 2). Myc-MST1 was immunoprecipitated from transiently transfected COS cells using the anti-myc antibody, 9E10 (lane 3). As a negative control COS cells were mock transfected with the vector alone (lane 4). Immunoprecipitations were incubated in kinase buffer containing [-P]ATP as described under ``Experimental Procedures.'' C, phosphoamino acid analysis of in vitro phosphorylated MST1 (B, auto) and myelin basic protein (B, MBP). Phosphoamino acids were resolved in one dimension using a pH 2.5 buffer(31) . Positions of unlabeled phosphoamino acids are indicated below the autoradiograph.



MST1 Is a Serine/Threonine Kinase

Endogenous MST1 was immunoprecipitated from COS cells using the m1-45 antiserum. As a negative control an equal amount of protein was incubated with preimmune serum. Each immunoprecipitate was used in an in vitro kinase assay alone or with myelin basic protein as a substrate. As shown in Fig. 4B, immunoprecipitated MST1 was able to phosphorylate itself and MBP. In vitro kinase assays using histone H1 and alpha-casein as substrates were performed; however, these proteins are poor substrates for MST1 (data not shown). In a similar experiment, immunoprecipitated Myc-MST1 was able to phosphorylate itself and MBP (Fig. 4B). To determine the phosphoamino acid content of in vitro phosphorylated endogenous MST1 and MBP, the radioactive bands in Fig. 4B were excised, eluted, and subjected to acid hydrolysis. This analysis revealed phosphorylation only on serine and threonine residues with MST1 phosphorylating itself primarily on threonine residues and MBP primarily on serine residues (Fig. 4C).

MST1 Does Not Activate the ERK1/2 MAPK Pathway

To determine if MST1 functions to activate the ERK1/2 pathway, COS cells were transiently transfected with Myc-MST1. Upon stimulation of starved COS cells with EGF, endogenous ERK1 is upshifted and kinase activity increases 8-fold; however, no upshift or increase in ERK1 kinase activity occurred when MST1 was overexpressed nor did overexpression of MST1 block activation of ERK1 by EGF (Fig. 5A).


Figure 5: MST1 does not activate ERK1/2. A-C, COS cells were transiently transfected with vector alone (lanes 1 and 2) or pCMV5-MMST1 (lanes 3 and 4), starved for 20 h, followed by treatment with EGF (400 ng/ml) for 10 min. Each lane contains 19 µg of lysate. A, lysates were separated in an SDS-polyacrylamide gel containing 0.25 mg/ml MBP followed by an in gel kinase assay as described under ``Experimental Procedures.'' B, Western blot using anti-MAPK antibodies. C, Western blot using anti-myc antibodies. The positions of ERK1/2 and full-length MST1 are indicated. D, kinetic analysis of endogenous MST1 following treatment with EGF for the indicated times. COS cells which had been starved for 20 h then treated with EGF were lysed and endogenous MST1 immunoprecipitated with the m1-45 antibody as described under ``Experimental Procedures.'' The upper panel is an in vitro kinase assay with MBP as the substrate, and the lower panel is a Western blot using the anti-MST1 antibody.



Western blot analysis of Myc-MST1 transfected COS cells with anti-Myc antibodies shows a protein migrating at 57 kDa consistent with the size of tagged MST1; however, a smaller protein (approximately 40 kDa) is also recognized that has significantly greater kinase activity than the p57 form (Fig. 5, A and C). Since the Myc-epitope is present on this faster migrating species, we conclude that it is a carboxyl-terminal truncation of MST1 and may indicate that a portion of the carboxyl terminus is inhibitory to kinase function. It is important to note that we do not see the p40 protein when MST1 is expressed from a weaker promoter (data not shown).

Treatment with EGF Causes a Decrease in MST1 Activity

Interestingly, in the above experiment EGF stimulation caused a 2-fold decrease in MST1 activity (Fig. 5A). Kinetic analysis indicates that the decrease in MST1 activity is maximal at 1 min and returns to the level seen prior to treatment by 30 min (Fig. 5D). MST1 activity was examined following treatment with calf serum, lysophosphatidic acid, 12-O-tetradecanoylphorbol-13-acetate, AlF(4), heat shock, or high salt; however, while positive controls were activated, MST1 activity was not affected (data not shown).

PP2A Treatment Stimulates MST1 Kinase Activity

To determine if the phosphorylation state of MST1 affected its kinase activity, immunoprecipitated HA-MST1 was treated with the protein serine/threonine phosphatase, PP2A, and subjected to an in gel kinase assay with MBP as the substrate. Immunoprecipitated HA-ERK1 with and without EGF stimulation is shown as a control. While stimulated ERK1 activity decreased substantially upon treatment with PP2A, MST1 activity increased 3-4-fold indicating that the enzyme may be negatively regulated by serine/threonine phosphorylation (Fig. 6). We do not believe the increase in activity is due to the removal of phosphate from potential autophosphorylation sites since in the absence of MBP an increase in kinase activity is not seen following treatment with PP2A (data not shown).


Figure 6: PP2A treatment stimulates MST1 kinase activity. COS cells were transiently transfected with vector alone, pJ3H-ERK1 or pJ3H-MST1, starved for 20 h, followed by treatment with EGF (400 ng/ml) for 10 min. After immunoprecipitation each sample with divided equally in two and treated with PP2A (0.5 unit) or mock treated with buffer alone as described under ``Experimental Procedures.'' A, PP2A treated immunoprecipitates were separated in an SDS-polyacrylamide gel containing 0.25 mg/ml MBP followed by an in gel kinase assay as described under ``Experimental Procedures.'' B, Western blot of indicated immunoprecipitates using anti-HA antibodies.




DISCUSSION

We have cloned and characterized a human protein kinase with considerable similarity to Ste20 and other Ste20-like kinases. Biochemical characterization of this kinase indicates that it is a prominent renaturable kinase in COS cells. We have tentatively named this kinase MST1 pending an assignment of a biological function. MST1 is expressed at approximately equal levels in all tissues. The MST1 protein is present in all human and monkey cell lines that we examined; however, it could not be detected in either rat cell line (Rat1A and PC12) and only at low levels in a mouse cell line (NIH3T3). We do not believe this is due to the inability of the MST1 polyclonal antiserum to recognize rodent MST1 since MST1 can be immunoprecipitated from NIH3T3 cells using the same antiserum (data not shown), rather MST1 is present at low levels in these lines.

An in vitro kinase assay using immunoprecipitated MST1 demonstrated that it can phosphorylate itself and an exogenous substrate, and phosphoamino acid analysis indicated that MST1 is a serine/threonine kinase. While MST1 kinase activity is readily detectable in an in vitro and in gel kinase assay, we do not believe MST1 is in its most active state for two reasons. First, treatment of MST1 immunoprecipitated from starved COS cells with PP2A results in an approximate 3-4-fold increase in kinase activity. We do not see any difference in MST1 activity throughout the cell cycle (data not shown); therefore, we do not believe that inhibition of activity is specific to quiescence. This result suggests that MST1 is held in a partially inactive state through serine/threonine phosphorylation. Second, a carboxyl-truncated form of MST1, arising apparently from proteolysis, is much more active than full-length MST1 (Fig. 5). This latter result indicates that the carboxyl terminus has an inhibitory role.

While the catalytic domains of MST1 and Ste20 are 64% similar, it is unable to complement a ste20 null allele in S. cerevisiae using a quantitative mating assay. Also, overexpression of MST1 does not activate ERK1/2 in COS cells. The inability of several growth factors, heat shock, or high osmolarity to increase MST1 activity indicates that MST1 is not involved in the MAPK or the HOG signal transduction cascades. The 2-3-fold decrease in MST1 activity following EGF stimulation, while modest, may indicate that MST1 is involved in a pathway which is affected by growth factors acting on tyrosine kinase receptors that is distinct from the MAPK pathway. However, because MST1 does not appear to be in its most active state, it is difficult to determine if a decrease in this low level of activity is biologically significant. The assignment of MST1 to a particular signal transduction cascade awaits identification of effectors of MST1 kinase activity and the target(s) of its catalytic activity.

At this time we do not understand the significance of the homologies between MST1, Ste20, and the other Ste20-like kinases. The kinase domains of all of these proteins are quite conserved and represent what is becoming a growing family of Ste20-like kinases. The high degree of similarity between Ste20 and p65, including the conservation of the Cdc42/Rac1 binding element, suggests that these proteins perform similar functions and may represent a distinct subfamily, while MST1, GC kinase, and SPS1 may be a part of another subfamily. Identification of substrates for these Ste20-like kinases may help determine the importance of these similarities.


FOOTNOTES

*
This work was supported in part by National Institutes of Health Grant RO1 CA58836 (to J. C.) and Postdoctoral Training Grant CA-09035 (to C. L. C.), and by W. W. Smith Foundation Grant C9201 (to J. C.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore by hereby marked ``advertisement'' in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

The nucleotide sequence(s) reported in this paper has been submitted to the GenBank(TM)/EMBL Data Bank with accession number(s) U18297[GenBank].

§
To whom correspondence should be addressed: Fox Chase Cancer Center, 7701 Burholme Ave., Philadelphia, PA 19111. Tel.: 215-728-5320; Fax: 215-728-3616; chernoff{at}boggy.ptp.fccc.edu.

(^1)
The abbreviations used are MAPK, mitogen-activated protein kinase; ERK, extracellular-signal regulated kinase; MEK MAP kinase/ERK-activating kinase; MEKK, MEK kinase; DMEM, Dulbecco's modified Eagle's medium; MBP, myelin basic protein; PAGE, polyacrylamide gel electrophoresis; EGF, epidermal growth factor; bp, base pair(s); kb, kilobase pair(s); HA, hemagglutinin; SAPK, stress-activated protein kinase; HOG, high osmolarity glycerol).

(^2)
M. A. Sells, U. G. Knaus, S. Bagrodia, D. Ambrose, G. M. Bokoch, and J. Chernoff, manuscript submitted for publication.


ACKNOWLEDGEMENTS

We thank S. Elledge for the YES library and Heng-Chun Li for the PP2A.


REFERENCES

  1. Cobb, M. H., Boulton, T. G., and Robbins, D. J. (1991) Cell Regul. 2,965-978 [Medline] [Order article via Infotrieve]
  2. Crews, C. M., Alessandrini, A., and Erikson, R. L. (1992) Cell Growth Differ. 3,135-142 [Abstract]
  3. Pelech, S. L., and Sanghera, J. S. (1992) Trends Biochem. Sci. 17,233-238 [Medline] [Order article via Infotrieve]
  4. Seth, A., Alvarez, E., Gupta, S., and Davis, R. J. (1991) J. Biol. Chem. 266,23521-23524 [Abstract/Free Full Text]
  5. Sturgill, T. W., Ray, L. B., Erikson, E., and Maller, J. L. (1988) Nature 334,715-718 [CrossRef][Medline] [Order article via Infotrieve]
  6. Ruderman, J. V. (1993) Curr. Opin. Cell Biol. 5,207-213 [Medline] [Order article via Infotrieve]
  7. Nakielny, S., Cohen, P., Wu, J., and Sturgill, T. (1992) EMBO J. 11,2123-2129 [Abstract]
  8. Wu, J., Michel, H., Rossomando, A., Haystead, T., Shabanowitz, J., Hunt, D. F., and Sturgill, T. W. (1992) Biochem. J. 285,701-705 [Medline] [Order article via Infotrieve]
  9. Lange-Carter, C. A., Pleiman, C. M., Gardner, A. M., Blumer, K. J., and Johnson, G. L. (1993) Science 260,315-319 [Medline] [Order article via Infotrieve]
  10. Huang, W., Alessandrini, A., Crews, C. M., and Erikson, R. L. (1993) Proc. Natl. Acad. Sci. U. S. A. 90,10947-10951 [Abstract]
  11. Blumer, K. J., and Johnson, G. L. (1994) Trends Biochem. Sci. 19,236-240 [CrossRef][Medline] [Order article via Infotrieve]
  12. Kurjan, J. (1993) Annu. Rev. Genet. 27,147-179 [CrossRef][Medline] [Order article via Infotrieve]
  13. Errede, B., and Levin, D. E. (1993) Curr. Opin. Cell Biol. 5,254-260 [Medline] [Order article via Infotrieve]
  14. Maeda, T., Wurgler-Murphy, S. M., and Salto, H. (1994) Nature 369,242-245 [CrossRef][Medline] [Order article via Infotrieve]
  15. Brewster, J. L., deValoir, T., Dwyer, N. D., Winter, E., and Gustin, M. C. (1993) Science 259,1760-1763 [Medline] [Order article via Infotrieve]
  16. Neiman, A. M. (1993) Trends Genet. 9,390-394 [Medline] [Order article via Infotrieve]
  17. Krisak, L., Strich, R., Winters, R. S., Hall, J. P., Mallory, M., Kreitzer, D., Tuan, R. S., and Winter, E. (1994) Genes & Dev. 8,2151-2161
  18. Friesen, H., Lunz, R., Doyle, S., and Segall, J. (1994) Genes & Dev. 8,2162- 2175
  19. Kyriakis, J. M., Banerjee, P., Nikolakaki, E., Dal, T., Rubie, E. A., Ahmad, M. F., Avruch, J., and Woodgett, J. R. (1994) Nature 369,156-160 [CrossRef][Medline] [Order article via Infotrieve]
  20. Derijard, B., Hibi, M., Wu, I.-H., Barrett, T., Su, B., Deng, T., Karin, M., and Davis, R. J. (1994) Cell 76,1025-1037 [Medline] [Order article via Infotrieve]
  21. Han, J., Lee, J. D., Bibbs, L., and Ulevitch, R. J. (1994) Science 265,808-811 [Medline] [Order article via Infotrieve]
  22. Freshney, N. W., Rawlinson, L., Guesdon, F., Jones, E., Cowley, S., and Hsuan, J. (1994) Cell 78,1039-1049 [Medline] [Order article via Infotrieve]
  23. Rouse, J., Cohen, P., Trigon, S., Mornage, M., Alonso-Llamazares, A., Zamanillo, D., Hunt, T., and Nebreda, A. R. (1994) Cell 78,1027-1037 [Medline] [Order article via Infotrieve]
  24. Neiman, A. M., Stevenson, B. J., Xu, H.-P., Sprague, G. F., Jr., Herkowitz, I., Wigler, M., and Marcus, S. (1993) Mol. Biol. Cell 4,107-120 [Abstract]
  25. Hughes, D. A., Ashworth, A., and Marshall, C. J. (1993) Nature 364,349-352 [CrossRef][Medline] [Order article via Infotrieve]
  26. Leberer, E., Dignard, D., Harcus, D., Thomas, D. Y., and Whiteway, M. (1992) EMBO J. 11,4815-4824 [Abstract]
  27. Ramer, S. W., and Davis, R. W. (1993) Proc. Natl. Acad. Sci. U. S. A. 90,452-456 [Abstract]
  28. Manser, E., Leung, T., Sallhuddin, H., Zhao, Z.-S., and Lim, L. (1994) Nature 367,40-46 [CrossRef][Medline] [Order article via Infotrieve]
  29. Katz, P., Whalen, G., and Kehrl, J. H. (1994) J. Biol. Chem. 269,16802-16809 [Abstract/Free Full Text]
  30. Elledge, S. J., Mulligan, J. T., Ramer, S. W., Spottswood, M., and Davis, R. W. (1991) Proc. Natl. Acad. Sci. U. S. A. 88,1731-1735 [Abstract]
  31. Ausubel, F. M. (1994) in Current Protocols in Molecular Biology (F. M. Ausubel, Brent, R., Kingston, R. E., Moore, D. D., Seidman, J. G., Smith, J. A., and Struhl, K., eds) John Wiley & Sons, New York
  32. Sells, M. A., and Chernoff, J. (1995) Gene 152,187-189 [CrossRef][Medline] [Order article via Infotrieve]
  33. Andersson, S., Davis, D. L., Dahlback, H., Jornvall, H., and Russell, D. W. (1989) J. Biol. Chem. 264,8222-8229 [Abstract/Free Full Text]
  34. Evan, G. L., Lewis, G. K., Ramsay, G., and Bishop, J. M. (1985) Mol. Cell. Biol. 8,551-556
  35. Laemmli, U. K. (1970) Nature 227,680-685 [Medline] [Order article via Infotrieve]
  36. Harlow, E., and Lane, D. (1988) Antibodies: A Laboratory Manual , p. 505, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
  37. Gotoh, Y., Moriyama, K., Matsuda, B., Okumura, E., Kishimoto, T., Kawasaki, H., Suzuki, K., Yahara, I., Sakai, H., and Nishida, E. (1991) EMBO J. 10,2661-2668 [Abstract]
  38. Kameshita, I., and Fujisawa, H. (1989) Anal. Biochem. 183,139-143 [Medline] [Order article via Infotrieve]
  39. Boyle, W. J., Van der Geer, R., and Hunter, T. (1991) Methods Enzymol. 201,110-148 [Medline] [Order article via Infotrieve]
  40. Jelinek, T., and Weber, M. J. (1993) Biotech. 15,628-630
  41. Cleveland, D. W., Fischer, S. G., Kirschner, M. W., and Laemmli, U. K. (1977) J. Biol. Chem. 252,1102-1106 [Abstract]
  42. Hanks, S. K., Quinn, A. M., and Hunter, T. (1988) Science 241,42-52 [Medline] [Order article via Infotrieve]

©1995 by The American Society for Biochemistry and Molecular Biology, Inc.